EORTC Melanoma Group sentinel node protocol identifies high rate of submicrometastases according to Rotterdam Criteria

European Journal of Cancer

Volumn 46, Issue 13, 2010, Pages 2414-2421

  Van Der Ploeg, Augustinus P T ^a   Van Akkooi, Alexander C J ^a   Schmitz, Paul I M ^a   Koljenovic, Senada ^a   Verhoef, Cornelis ^a   Eggermont, Alexander M M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Melanoma; Multivariate analysis; Prognostic factors; Sentinel node

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MELANOMA; MICROMETASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SENTINEL LYMPH NODE; TUMOR VOLUME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; YOUNG ADULT;

EID: 77955919194     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.06.003     Document Type: Article

References (41)

1. D.L. Morton, D.R. Wen, and J.H. Wong Technical details of intraoperative lymphatic mapping for early stage melanoma Arch Surg 127 4 1992 392 399
2. D.L. Morton, J.F. Thompson, and A.J. Cochran Sentinel-node biopsy or nodal observation in melanoma New Engl J Med 355 13 2006 1307 1317
3. C.M. Balch, S.J. Soong, and J.E. Gershenwald Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system J Clin Oncol 19 16 2001 3622 3634
4. A.C. van Akkooi, J.H. de Wilt, and C. Verhoef High positive sentinel node identification rate by EORTC Melanoma Group protocol. Prognostic indicators of metastatic patterns after sentinel node biopsy in melanoma Eur J Cancer 42 3 2006 372 380
5. M.G. Cook, M.A. Green, and B. Anderson The development of optimal pathological assessment of sentinel lymph nodes for melanoma J Pathol 200 3 2003 314 319
6. A.C. van Akkooi, J.H. de Wilt, and C. Verhoef Clinical relevance of melanoma micrometastases (<0.1 mm) in sentinel nodes: are these nodes to be considered negative? Ann Oncol 17 10 2006 1578 1585
7. A. Testori, G.L. De Salvo, and M.C. Montesco Clinical considerations on sentinel node biospy in melanoma from an Italian Multicentric Study on 1,313 patients (SOLISM-IMI) Ann Surg Oncol 16 2009 2018 2027
8. G.W. Carlson, D.R. Murray, and R.H. Lyles The amount of metastatic melanoma in a sentinel lymph node: does it have prognostic significance? Ann Surg Oncol 10 5 2003 575 581
9. G.W. Carlson, A.J. Page, and C. Cohen Regional recurrence after negative sentinel lymph node biopsy for melanoma Ann Surg 248 3 2008 378 386
10. N. Cascinelli, E. Bombardieri, and R. Bufalino Sentinel and nonsentinel node status in stage IB and II melanoma patients: two-step prognostic indicators of survival J Clin Oncol 24 27 2006 4464 4471
11. A. Doubrovsky, J.H. De Wilt, R.A. Scolyer, W.H. McCarthy, and J.F. Thompson Sentinel node biopsy provides more accurate staging than elective lymph node dissection in patients with cutaneous melanoma Ann Surg Oncol 11 9 2004 829 836
12. S.H. Estourgie, O.E. Nieweg, R.A. Valdes Olmos, C.A. Hoefnagel, and B.B. Kroon Review and evaluation of sentinel node procedures in 250 melanoma patients with a median follow-up of 6 years Ann Surg Oncol 10 6 2003 681 688
13. J.E. Gershenwald, R.H. Andtbacka, and V.G. Prieto Microscopic tumor burden in sentinel lymph nodes predicts synchronous nonsentinel lymph node involvement in patients with melanoma J Clin Oncol 26 26 2008 4296 4303
14. J.E. Gershenwald, W. Thompson, and P.F. Mansfield Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients J Clin Oncol 17 3 1999 976 983
15. M. Guggenheim, R. Dummer, and F.J. Jung The influence of sentinel lymph node tumour burden on additional lymph node involvement and disease-free survival in cutaneous melanoma-a retrospective analysis of 392 cases Brit J Cancer 98 12 2008 1922 1928
16. S. Kettlewell, C. Moyes, and C. Bray Value of sentinel node status as a prognostic factor in melanoma: prospective observational study BMJ 332 7555 2006 1423
17. I. Koskivuo, L. Talve, and P. Vihinen Sentinel lymph node biopsy in cutaneous melanoma: a case-control study Ann Surg Oncol 14 12 2007 3566 3574
18. L. Kretschmer, I. Beckmann, and K.M. Thoms Sentinel lymphonodectomy does not increase the risk of loco-regional cutaneous metastases of malignant melanomas Eur J Cancer 41 4 2005 531 538
19. M. Mandala, G. Imberti, and D. Piazzalunga Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database Eur J of Cancer 45 14 2009 2537 2545
20. Z.I. Nowecki, P. Rutkowski, A. Nasierowska-Guttmejer, and W. Ruka Survival analysis and clinicopathological factors associated with false-negative sentinel lymph node biopsy findings in patients with cutaneous melanoma Ann Surg Oncol 13 12 2006 1655 1663
21. F. Roka, H. Kittler, and P. Cauzig Sentinel node status in melanoma patients is not predictive for overall survival upon multivariate analysis Brit J Cancer 92 4 2005 662 667
22. F. Roka, P. Mastan, and M. Binder Prediction of non-sentinel node status and outcome in sentinel node-positive melanoma patients Eur J Surg Oncol 34 1 2008 82 88
23. D. Roulin, M. Matter, and P. Bady Prognostic value of sentinel node biopsy in 327 prospective melanoma patients from a single institution Eur J Surg Oncol 34 6 2008 673 679
24. S. Sassen, H.M. Shaw, M.H. Colman, R.A. Scolyer, and J.F. Thompson The complex relationships between sentinel node positivity, patient age, and primary tumor desmoplasia: analysis of 2303 melanoma patients treated at a single center Ann Surg Oncol 15 2 2008 630 637
25. R.P. Scheri, R. Essner, R.R. Turner, X. Ye, and D.L. Morton Isolated tumor cells in the sentinel node affect long-term prognosis of patients with melanoma Ann Surg Oncol 14 10 2007 2861 2866
26. R.J. Vuylsteke, P.A. van Leeuwen, and M.G. Statius Muller Clinical outcome of stage I/II melanoma patients after selective sentinel lymph node dissection: long-term follow-up results J Clin Oncol 21 6 2003 1057 1065
27. V.S. Yee, J.F. Thompson, and J.G. McKinnon Outcome in 846 cutaneous melanoma patients from a single center after a negative sentinel node biopsy Ann Surg Oncol 12 6 2005 429 439
28. I.M.C. van der Ploeg, B.B.R. Kroon, N. Antonini, R.A. Valdes Olmos, and O.E. Nieweg Comparison of three micromorphometreic pathology classifications of melanoma metastases in the sentinel node Ann Surg 250 2009 301 304
29. A.H. Chakera, B. Hesse, and Z. Burak EANM-EORTC general recommendations for sentinel node diagnostics in melanoma Eur J Nucl Med Mol Imaging 36 10 2009 1713 1742
30. A.C.J. van Akkooi, Z. Nowecki, and C. Voit Minimal sentinel node (SN) tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients. A multicenter study in 388 SN positive patients Ann Surg 248 6 2008
31. ClinicalTrials.gov. Multicenter Selective Lymphadenectomy Trial (MSLT), NCT00275496; 2008. Available from: http://clinicaltrials.gov/ct2/show/record/ NCT00275496?term=mslt&rank=3.
32. Melanomagroup.eu. MINITUB Registration Study; 2009.
33. O.E. Nieweg False-negative sentinel node biopsy Ann Surg Oncol 16 8 2009 2089 2091
34. W.R. Wrightson, S.L. Wong, and M.J. Edwards Complications associated with sentinel lymph node biopsy for melanoma Ann Surg Oncol 10 6 2003 676 680
35. P. Beitsch, and C. Balch Operative morbidity and risk factor assessment in melanoma patients undergoing inguinal lymph node dissection Am J Surg 164 5 1992 462 465 discussion 5-6
36. D.L. Morton, A.J. Cochran, and J.F. Thompson Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial Ann Surg 242 3 2005 302 311 discussion 11-13
37. A.C. van Akkooi, M.G. Bouwhuis, and A.N. van Geel Morbidity and prognosis after therapeutic lymph node dissections for malignant melanoma Eur J Surg Oncol 33 1 2007 102 108
38. R.A. Scolyer, R. Murali, I. Satzger, and J.F. Thompson The detection and significance of melanoma micrometastases in sentinel nodes Surg Oncol 17 3 2008 165 174
39. M.M. Guggenheim, U. Hug, and F.J. Jung Morbidity and recurrence after completion lymph node dissection following sentinel lymph node biopsy in cutaneous malignant melanoma Ann Surg 247 4 2008 687 693
40. A.M. Eggermont, S. Suciu, and R. MacKie Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial Lancet 366 9492 2005 1189 1196
41. A.M. Eggermont, S. Suciu, and M. Santinami Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial Lancet 372 9633 2008 117 126